Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2011-01-18
2011-01-18
Bunner, Bridget E (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C435S069400, C435S069700
Reexamination Certificate
active
07872107
ABSTRACT:
Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
REFERENCES:
patent: 4196265 (1980-04-01), Koprowski et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5082658 (1992-01-01), Palladino
patent: 5091513 (1992-02-01), Huston et al.
patent: 5114711 (1992-05-01), Bell et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5196320 (1993-03-01), Gillies
patent: 5199942 (1993-04-01), Gillis
patent: 5225538 (1993-07-01), Capon et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5314995 (1994-05-01), Fell, Jr. et al.
patent: 5359035 (1994-10-01), Habermann
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5457038 (1995-10-01), Trinchieri et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5541087 (1996-07-01), Lo et al.
patent: 5585097 (1996-12-01), Bolt et al.
patent: 5601819 (1997-02-01), Wong et al.
patent: 5645835 (1997-07-01), Fell, Jr. et al.
patent: 5650150 (1997-07-01), Gillies
patent: 5650492 (1997-07-01), Gately et al.
patent: 5677425 (1997-10-01), Bodmer et al.
patent: 5679543 (1997-10-01), Lawlis
patent: 5723125 (1998-03-01), Chang et al.
patent: 5726044 (1998-03-01), Lo et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5827516 (1998-10-01), Urban et al.
patent: 5827703 (1998-10-01), Debs et al.
patent: 5843423 (1998-12-01), Lyman et al.
patent: 5858347 (1999-01-01), Bauer et al.
patent: 5891680 (1999-04-01), Lieschke et al.
patent: 5908626 (1999-06-01), Chang et al.
patent: 5922685 (1999-07-01), Rakhmilevich et al.
patent: 5994104 (1999-11-01), Anderson et al.
patent: 6100387 (2000-08-01), Herrmann et al.
patent: 6309636 (2001-10-01), de Couto et al.
patent: 6335176 (2002-01-01), Inglese et al.
patent: 6475717 (2002-11-01), Enssle et al.
patent: 6617135 (2003-09-01), Gillies et al.
patent: 6627615 (2003-09-01), Debs et al.
patent: 6646113 (2003-11-01), Dreyfuss et al.
patent: 6838260 (2005-01-01), Gillies et al.
patent: 6838360 (2005-01-01), Kumazaki et al.
patent: 6969517 (2005-11-01), Gillies et al.
patent: 7091321 (2005-11-01), Gillies et al.
patent: 6992174 (2006-01-01), Gillies et al.
patent: 7067110 (2006-06-01), Gillies et al.
patent: 7141651 (2006-11-01), Gillies et al.
patent: 7148321 (2006-12-01), Gillies et al.
patent: 7169904 (2007-01-01), Gillies et al.
patent: 7186804 (2007-03-01), Gillies et al.
patent: 2002/0034765 (2002-03-01), Daugherty et al.
patent: 2002/0037558 (2002-03-01), Lo et al.
patent: 2002/0081664 (2002-06-01), Lo et al.
patent: 2002/0146388 (2002-10-01), Gillies
patent: 2002/0147311 (2002-10-01), Gillies et al.
patent: 2002/0193570 (2002-12-01), Gillies et al.
patent: 2003/0133939 (2003-01-01), Ledbetter et al.
patent: 2003/0044423 (2003-03-01), Gillies et al.
patent: 2003/0049227 (2003-03-01), Gillies et al.
patent: 2003/0105294 (2003-06-01), Gillies et al.
patent: 2003/0139365 (2003-07-01), Lo et al.
patent: 2003/0139575 (2003-07-01), Gillies
patent: 2003/0153043 (2003-08-01), Carr et al.
patent: 2003/0157054 (2003-08-01), Gillies et al.
patent: 2003/0166163 (2003-09-01), Gillies
patent: 2003/0166877 (2003-09-01), Gillies et al.
patent: 2004/0033210 (2004-02-01), Gillies
patent: 2004/0043457 (2004-03-01), Schumacher et al.
patent: 2004/0053366 (2004-03-01), Lo et al.
patent: 2004/0072299 (2004-04-01), Gillies et al.
patent: 2004/0082039 (2004-04-01), Gillies et al.
patent: 2004/0180035 (2004-09-01), Gillies et al.
patent: 2004/0180386 (2004-09-01), Carr et al.
patent: 2004/0203100 (2004-10-01), Gillies et al.
patent: 2005/0042729 (2005-02-01), Lo et al.
patent: 2005/0069521 (2005-03-01), Gillies et al.
patent: 2005/0137384 (2005-06-01), Gillies et al.
patent: 2005/0164352 (2005-07-01), Lauder et al.
patent: 2005/0192211 (2005-07-01), Lauder et al.
patent: 2005/0202021 (2005-09-01), Gillies et al.
patent: 2005/0202538 (2005-09-01), Gillies et al.
patent: 2005/0244418 (2005-11-01), Gillies et al.
patent: 2005/0261229 (2005-11-01), Gillies et al.
patent: 2006/0025573 (2006-02-01), Gillies et al.
patent: 2006/0034836 (2006-02-01), Gillies et al.
patent: 2006/0141581 (2006-06-01), Gillies et al.
patent: 2006/0194952 (2006-08-01), Gillies et al.
patent: 2006/0228332 (2006-10-01), Gillies et al.
patent: 2006/0263856 (2006-10-01), Gillies et al.
patent: 2007/0036752 (2007-02-01), Gillies et al.
patent: 21725/88 (1989-03-01), None
patent: 0 294 703 (1988-12-01), None
patent: 0 308 936 (1989-03-01), None
patent: 0 314 317 (1989-05-01), None
patent: 0 318 554 (1989-06-01), None
patent: 0 326 120 (1989-08-01), None
patent: 0 428 596 (1991-05-01), None
patent: 0 433 827 (1991-06-01), None
patent: 0 439 095 (1991-07-01), None
patent: 0 511 747 (1992-11-01), None
patent: 0 601 043 (1994-06-01), None
patent: 0 659 439 (1995-06-01), None
patent: 0 790 309 (1997-08-01), None
patent: 1 088 888 (2001-04-01), None
patent: 1 176 195 (2002-01-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 89/09620 (1989-10-01), None
patent: WO 91/04329 (1991-04-01), None
patent: WO 91/08298 (1991-06-01), None
patent: WO 91/13166 (1991-09-01), None
patent: WO 92/02240 (1992-02-01), None
patent: WO 92/08495 (1992-05-01), None
patent: WO 92/08801 (1992-05-01), None
patent: WO 92/10755 (1992-06-01), None
patent: WO 92/16562 (1992-10-01), None
patent: WO 93/03157 (1993-02-01), None
patent: WO 94/25609 (1994-11-01), None
patent: WO 95/05468 (1995-02-01), None
patent: WO 96/08570 (1996-03-01), None
patent: WO 97/00317 (1997-01-01), None
patent: WO 97/20062 (1997-06-01), None
patent: WO 97/24137 (1997-07-01), None
patent: WO 97/30089 (1997-08-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 99/29732 (1999-06-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 01/18051 (2001-03-01), None
patent: WO 01/40257 (2001-06-01), None
patent: WO 02/056910 (2002-07-01), None
patent: WO 02/069232 (2002-09-01), None
patent: WO 02/079232 (2002-10-01), None
Hasan et al, 1999 (Journal of Immunology. 162: 1064-1070).
Campanella et al, 2003 (Journal of Biological Chemistry. 278(19): 17066-17074).
Russell et al, 2004, Journal of Immunology, 171: 6866-6874.
Ferrer-Costa (2007. J Mol Biol. 365: 249-256).
Wells (1990) Biochemistry 29(37): 8509-8517.
Ngo et al (1994) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 433-440 and 492-495 only.
Bork (2000) Genome Research 10:398.
Skolnick et al (2000) Trends in Biotech. 18(1): 34.
Doerks et al (1998) Trends in Genetics 14(6): 248.
Brenner (1999) Trends in Genetics 15(4): 132.
Stenlund et al (2002. Biochemistry. 41: 3168-3175).
Lefevre et al, 1997 (Nucleic Acids Research. 25(2):447-448).
Paine-Saunders et al, 2002 (Journal of Biological Chemistry. 277(3): 2089-2096).
Afonso et al., (1994), “The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania Major,”Science, 263:235-237.
Barbulescu et al., (1998), “IL-12 and IL-18 Differentially Regulate the Transcriptional Activity of the Human IFN-γ Promoter in Primary CD4+ T Lymphocytes,”J. Immunol., 160:3642-7.
Batova et al., (1999), “The Ch14.18-GM-CSF Fusion Protein is Effective at Mediating Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity in Vitro,”Clinical Cancer Research, 5:4259-4263.
Becker et al., (1996), “An Antibody-Interleukin 2 Fusion Protein Overcomes Tumor Heterogeneity by Induction of a Cellular Immune Response,”Proc. Natl. Acad. Sci. USA, 93:7826-7831.
Becker et al., (1996), “Eradication of Human Hepatic and Pulmonary Melanoma Metastases in SCID Mice by Antibody-Interleukin 2 Fusion Proteins,”Proc. Natl. Acad. Sci. USA, 93:2702-2707.
Becker et al., (19
Lo Kin-Ming
McKenzie Suzanne P.
Stein Pascal André
Webster Gordon D.
Bunner Bridget E
Goodwin & Procter LLP
Howard Zachary C
Merck Patent GmbH
LandOfFree
Interleukin-12p40 variants with improved stability does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-12p40 variants with improved stability, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-12p40 variants with improved stability will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2659366